Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein

Inhibition of cyclin dependent kinases (CDKs) 4 and 6 prevent cells from entering the synthesis phase of the cell cycle. CDK4 and 6 are therefore important drug targets in various cancers. The selective CDK4/6 inhibitor palbociclib is approved for the treatment of breast cancer and has shown activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez Maganhi, Stella, Jensen, Patrizia, Caracelli, Ignez, Zukerman Schpector, Julio, Fröhling, Stefan, Friedman, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368058/
https://www.ncbi.nlm.nih.gov/pubmed/28168755
http://dx.doi.org/10.1002/pro.3135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368058/
https://www.ncbi.nlm.nih.gov/pubmed/28168755
http://dx.doi.org/10.1002/pro.3135

Ejemplares similares